- Title: Subtitle
- Evaluation of chenodeoxycholic acid treatment in adult patients with cerebrotendinous xanthomatosis: A randomized, placebo-controlled Phase 3 study (RESTORE)
- Creators
- Andrea DeBarber - University of PortlandYaz Kisanuki - The Ohio State University Wexner Medical CenterPaulo Nobrega - Hospital Universitário Walter CantídioRyan Himes - Ochsner Medical CenterSuman Jayadev - University of WashingtonJohn Bernat - University of IowaVikram Prakash - Orlando HealthJames Gibson - Dell Children's Medical Center of Central TexasAustin Larson - Children's Hospital ColoradoPaulo Sgobbi - Universidade Federal de São PauloEdward Murphy - Travere Therapeutics, San Diego, CA, United StatesBrian Fedor - Travere Therapeutics, San Diego, CA, United StatesCheryl Wong Po Foo - Travere Therapeutics, San Diego, CA, United StatesRana Dutta - Mirum Pharmaceuticals, Inc., Foster City, CA, United StatesMichael Imperiale - Mirum Pharmaceuticals, Inc., Foster City, CA, United StatesWill Garner - Mirum Pharmaceuticals, Inc., Foster City, CA, United StatesPamela Vig - Mirum Pharmaceuticals, Inc., Foster City, CA, United StatesP. Barton Duell - University of PortlandSarah Perez - Tulane UniversityRitesh Ramdhani - Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
- Resource Type
- Abstract
- Publication Details
- Molecular genetics and metabolism, Vol.141(4), 108216
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.ymgme.2024.108216
- ISSN
- 1096-7192
- eISSN
- 1096-7206
- Language
- English
- Date published
- 04/2024
- Academic Unit
- Stead Family Department of Pediatrics; Medical Genetics and Genomics
- Record Identifier
- 9984583618402771
Abstract
Evaluation of chenodeoxycholic acid treatment in adult patients with cerebrotendinous xanthomatosis: A randomized, placebo-controlled Phase 3 study (RESTORE)
Molecular genetics and metabolism, Vol.141(4), 108216
04/2024
DOI: 10.1016/j.ymgme.2024.108216
Details
Metrics
14 Record Views